Patents by Inventor Anuschirwan Peyman
Anuschirwan Peyman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7435747Abstract: The present invention relates to compounds of the formula I, in which R0; Q; X; Q?, D, R10 and V have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: GrantFiled: July 7, 2004Date of Patent: October 14, 2008Assignee: Sanofi-Aventis Deutschland GmbHInventors: Anuschirwan Peyman, David William Will, Uwe Gerlach, Marc Nazaré, Gerhard Zoller, Hans-Peter Nestler, Hans Matter, Fahad Al-Obeidi
-
Patent number: 7259159Abstract: The present invention relates to acylguanidino derivatives of formula (I), in which R1, R2, R3, A, B, X, Y and n have the meanings indicated in claim 1, their physiologically tolerable salts and their prodrugs. The compounds of the formula (I) are valuable pharmaceutically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and bone resorption by osteoclasts. This renders them suitable, for example, for the therapy and prophylaxis of illness which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth muscles.Type: GrantFiled: July 23, 2001Date of Patent: August 21, 2007Assignees: Sanofi-Aventis Deutschland GmbH, Genentech Inc.Inventors: Anuschirwan Peyman, David Will, Thomas R Gadek, Robert McDowell, Jean Francois Gourvest, Jean-Marie Ruxer, Jochen Knolle
-
Patent number: 7229974Abstract: Oligonucleotides of the formula 5?-(CAP)-(Oligo)-(CAP)-3? are disclosed where (oligo) is a nucleotide sequence of from 10 to 40 nucleotides in length, and CAP is Gm, where m is an integer of from zero to ten, the two CAP's which are present in the molecule can be defined independently of each other and must be different in the case where m is zero at the 5? or 3? end and the end of the Oligo sequence is other than guanine. The oligonucleotides can be synthesized chemically. The oligonucleotides are used to diagnose or treat cancer, restenosis, a disease caused by a virus, a disease affected by integrins or cell-cell adhesion receptor or a disease triggered by diffusible factors.Type: GrantFiled: May 21, 2001Date of Patent: June 12, 2007Assignee: Sanofi-Aventis Deutschland GmbHInventors: Anuschirwan Peyman, Eugen Uhlmann
-
Patent number: 7067665Abstract: The present invention relates to compounds comprising the following formula: R0-Q-X-Q?-W-U-V-G-M??(I) These compounds are useful as pharmacologically active compounds. They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders such as thromboembolic diseases or restenoses. These compounds are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can generally be used to treat, prevent, or cure conditions in which an undesired activity of factor Xa and/or factor VIIa is present, or where inhibition of factor Xa and/or factor VIIa is intended. The invention further relates to processes for the preparation of these compounds, methods of their use (e.g., as active ingredients in pharmaceuticals), and pharmaceutical preparations comprising them.Type: GrantFiled: January 19, 2005Date of Patent: June 27, 2006Assignee: Sanofi-Aventis Deutschland GmbHInventors: Marc Nazare, David William Will, Anuschirwan Peyman, Hans Matter, Gerhard Zoller, Uwe Gerlach
-
Patent number: 6992187Abstract: A process for the preparation of a compound of the formula wherein the substituents are defined as in the specification.Type: GrantFiled: August 29, 2001Date of Patent: January 31, 2006Assignee: Aventis Pharma Deutschland GmbHInventors: Anuschirwan Peyman, Gerrit Schubert
-
Patent number: 6953857Abstract: The present invention relates to compounds comprising the following formula: R0—Q—X—Q?—W—U—V—G—M??(I) These compounds are useful as pharmacologically active compounds. They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders such as thromboembolic diseases or restenoses. These compounds are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can generally be used to treat, prevent, or cure conditions in which an undesired activity of factor Xa and/or factor VIIa is present, or where inhibition of factor Xa and/or factor VIIa is intended. The invention further relates to processes for the preparation of these compounds, methods of their use (e.g., as active ingredients in pharmaceuticals), and pharmaceutical preparations comprising them.Type: GrantFiled: December 21, 2001Date of Patent: October 11, 2005Assignee: Aventis Pharma Deutschland GmbHInventors: Marc Nazaré, David William Will, Anuschirwan Peyman, Hans Matter, Gerhard Zoller, Uwe Gerlach
-
Publication number: 20050165058Abstract: The present invention relates to compounds comprising the following formula: R0-Q-X-Q?-W—U—V-G-M??(I) These compounds are useful as pharmacologically active compounds. They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders such as thromboembolic diseases or restenoses. These compounds are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can generally be used to treat, prevent, or cure conditions in which an undesired activity of factor Xa and/or factor VIIa is present, or where inhibition of factor Xa and/or factor VIIa is intended. The invention further relates to processes for the preparation of these compounds, methods of their use (e.g., as active ingredients in pharmaceuticals), and pharmaceutical preparations comprising them.Type: ApplicationFiled: January 19, 2005Publication date: July 28, 2005Applicant: Aventis Pharma Deutschland GmbHInventors: Marc Nazare, David Will, Anuschirwan Peyman, Hans Matter, Gerhard Zoller, Uwe Gerlach
-
Publication number: 20050148017Abstract: Antisense oligonucleotides against tenascin for the treatment of vitiligo The invention relates to specific, optionally modified oligonucleotides having a length of up to 18 nucleotides, which correspond to sections of tenascin-coding sequences or can bind to these sequences, to their preparation and to the use thereof, for example for the specific inhibition of the expression of tenascin and for the production of pharmaceuticals which can be used for the treatment of vitiligo.Type: ApplicationFiled: March 4, 2005Publication date: July 7, 2005Applicant: Aventis Pharma Deutschland GmbHInventors: Anuschirwan Peyman, Eugen Uhlmann, Caroline Weiser
-
Publication number: 20050143419Abstract: The present invention relates to compounds of the formula I, in which R0; Q; X; Q?, D, R10 and V have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: ApplicationFiled: July 7, 2004Publication date: June 30, 2005Applicant: Aventis Pharma Deutschland GmbHInventors: Anuschirwan Peyman, David Will, Uwe Gerlach, Marc Nazare, Gerhard Zoller, Hans-Peter Nestler, Hans Matter, Fahad Al-Obeidi
-
Patent number: 6878547Abstract: The invention relates to specific, optionally modified oligonucleotides with a length of up to 17 nucleotides. Said oligonucleotides correspond to segments of tenascin-coding sequences or can bind to these sequences. The invention also relates to the production and use of the oligonucleotides, for example for the specific inhibition of the expression of tenascin and for producing medicaments used to treat vitiligo.Type: GrantFiled: October 29, 1998Date of Patent: April 12, 2005Assignee: Aventis Pharma Deutschland GmbHInventors: Anuschirwan Peyman, Eugen Uhlmann, Caroline Weiser
-
Patent number: 6867208Abstract: The present invention relates to compounds of the formula I A—B—D—E—F—G??(I) in which A, B, D, E, F and G have the meanings given in the patent claims, to their preparation and to their use as medicaments. The compounds of the invention are used as vitronectin receptor antagonists and as inhibitors of bone resorption.Type: GrantFiled: May 13, 2002Date of Patent: March 15, 2005Assignees: Hoechst Aktiengesellschaft, Genentech, Inc.Inventors: Volkmar Wehner, Hans Ulrich Stilz, Anuschirwan Peyman, Jochen Knolle, Jean-Marie Ruxer, Denis Carniato, Jean-Michel Lefrancois, Thomas Richard Gadek, Robert McDowell
-
Patent number: 6867213Abstract: (2S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use The present invention relates to (2S)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester of the formula I and its physiologically tolerable salts, their preparation, their use as pharmaceuticals and to pharmaceutical compositions comprising them. The compound of the formula I and its physiologically tolerable salts are valuable pharmacologically active compounds which can be used, for example, in the treatment or prophylaxis of diseases which can be influenced by inhibiting the vitronectin receptor, for example of bone diseases such as osteoporosis.Type: GrantFiled: September 27, 2001Date of Patent: March 15, 2005Assignees: Aventis Pharma Deutschland GmbHInventors: Anuschirwan Peyman, Theodor Wollmann, Gerhard Brejpohl, Jean-Francois Gourvest, Jean-Marie Ruxer, Thomas Gadek, Robert McDowell
-
Publication number: 20050020523Abstract: The invention relates to a specific modified oligonucleotide complementary to a section of the human Ha-ras gene and mRNA, and its use to specifically regulate, modulate or inhibit expression of the HA-ras gene, and its use as a pharmaceutical for the treatment of conditions arising from the abnormal expression of the Ha-Ras gene, in particular in combination with chemotherapy and radiotherapy.Type: ApplicationFiled: December 11, 2003Publication date: January 27, 2005Applicant: Aventis Pharma Deutschland GmbHInventors: Eugen Uhlmann, Anuschirwan Peyman, David Will, Esther Chang, Kathleen Pirollo, Antonina Rait
-
Patent number: 6762190Abstract: The present invention relates to compounds of formula (I), in which A, B, X, Y, R1, R2, R3 and n have the meanings indicated in the claims. The compounds of formula (I) are valuable pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention furthermore relates to processes for the preparation of compounds of formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.Type: GrantFiled: September 23, 2002Date of Patent: July 13, 2004Assignee: Aventis Pharma S.A. Deutschland GmbH Genentech, Inc.Inventors: Thomas Gadek, Jean-Francois Gourvest, Anuschirwan Peyman, Jean-Marie Ruxer, Karl-Heinz Scheunemann
-
Patent number: 6747016Abstract: The present invention relates to compounds of formula (I), in which B, D, E, G, X, Y, Z, R1, R2 and s have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of formula (I) are valuable pharmacologically active compounds. They are vitronectin receptor antagonist and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or prolifertion of cells of the vascular smooth musculature.Type: GrantFiled: March 6, 2002Date of Patent: June 8, 2004Assignees: Aventis Pharma Deutschland GmbH, Genetech Inc.Inventors: Anuschirwan Peyman, Jochen Knolle, Thomas R Gadek, Jean-Francois Gourvest, Jean-Marie Ruxer
-
Patent number: 6747148Abstract: Sulfonamide derivatives, their physiologically tolerable salts and their prodrugs according to the present invention are vitronectin receptor antagonists and inhibitors of cell adhesion, as well as inhibit bone resorption by osteoclasts. These derivatives, salts and prodrugs are pharmaceutically active compounds useful in the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. Processes for the preparation of the sulfonamide derivatives according to the present invention, the use of these derivatives as pharmaceutically active ingredients, and pharmaceutical preparations comprising these derivatives also are disclosed.Type: GrantFiled: October 9, 2001Date of Patent: June 8, 2004Assignees: Hoechst Marion Roussel Deutschland GmbH, Genentech, Inc.Inventors: Anuschirwan Peyman, David William Will, Jochen Knolle, Karlheinz Scheunemann, Denis Carniato, Jean-Francois Gourvest, Thomas R. Gadek, Robert McDowell, Sarah Catherine Bodary, Robert Andrew Cuthbertson
-
Patent number: 6723706Abstract: The invention relates to a specific modified oligonucleotide complementary to a section of the human Ha-ras gene and mRNA, and its use to specifically regulate, modulate or inhibit expression of the HA-ras gene, and its use as a pharmaceutical for the treatment of conditions arising from the abnormal expression of the Ha-Ras gene, in particular in combination with chemotherapy and radiotherapy.Type: GrantFiled: February 17, 2000Date of Patent: April 20, 2004Assignee: Aventis Pharma Deutschland GmbHInventors: Eugen Uhlmann, Anuschirwan Peyman, David William Will, Esther Chang, Kathleen Pirollo, Antonina Rait
-
Patent number: 6723727Abstract: The present invention relates to compounds of the formulae I and Ia in which X, Y, W, Wa, G and Ga have the meanings given in the patent claims, and their physiologically tolerable salts and their prodrugs, their preparation, their use, in particular as pharmaceutical active compounds, and pharmaceutical preparations comprising them. The compounds of the formula I are vitronectin receptor antagonists and can be employed, for example, as inhibitors of bone resorption and for the treatment of osteoporosis.Type: GrantFiled: June 15, 2000Date of Patent: April 20, 2004Assignees: Hoechst Aktiengesellschaft, GenentechInventors: Anuschirwan Peyman, Jochen Knolle, Volkmar Wehner, Gerhard Breipohl, Jean-Francois Gourvest, Denis Carniato, Thomas Richard Gadek
-
Publication number: 20030176384Abstract: The present invention relates to an antisense oligonucleotide or a derivative thereof which has a sequence that corresponds to a part of a nucleic acid which encodes an integrin &agr;v subunit and which has the ability to induce apoptosis, the preparation and the use thereof.Type: ApplicationFiled: November 6, 2002Publication date: September 18, 2003Inventors: Eugen Uhlmann, Anuschirwan Peyman, Anna Maria Teti, Ida Villanova
-
Publication number: 20030119785Abstract: The present invention relates to compounds of the formula I,Type: ApplicationFiled: November 19, 2002Publication date: June 26, 2003Applicant: Hoechst Aktiengesellschaft and Genentech Inc.Inventors: Volkmar Wehner, Hans Ulrich Stilz, Anuschirwan Peyman, Karlheinz Scheunemann, Jean-Marie Ruxer, Denis Carniato, Jean-Michel Lefrancois, Thomas Richard Gadek, Robert McDowell